-
1.发明公开公开(公告)号：US20240270758A1
公开(公告)日：2024-08-15
申请号：US18558139
申请日：2022-04-29
发明人： Tao Jiang , Fusheng Zhou , Leitao Zhang , Lijian Cai , Xiaoming Xu , Kai Ma , Zhubo Liu , Jiong Lan
IPC分类号： C07D519/00 , A61K31/517 , A61K31/519 , A61P35/00
CPC分类号： C07D519/00 , A61K31/517 , A61K31/519 , A61P35/00
摘要： Provided is a pyridino- or pyrimido-cyclic compound having an inhibitory effect on a KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, wherein the structure of the compound is as shown in formula (AI) or (AII), and the definition of each group in the formula is detailed in the description. In addition, also disclosed are a pharmaceutical composition comprising the compound, and the use thereof in the preparation of a cancer drug.
-
公开(公告)号：US20220363681A1
公开(公告)日：2022-11-17
申请号：US17635938
申请日：2020-08-12
发明人： Fusheng ZHOU , Tao JIANG , Wan HE , Zhubo LIU , Leitao ZHANG , Jiong LAN
IPC分类号： C07D471/10 , C07D401/14 , C07D405/14 , C07D403/14 , C07D471/04 , C07D471/08
摘要： Provided is an oxygen-substituted six-membered ring pyrimidine compound with selective inhibitory effect on KRAS gene mutation and a pharmaceutically acceptable salt, a stereoisomer, a solvate, or a prodrug thereof, as represented by formula (I). The definition of each group or symbol in the formula is detailed in the specification. Moreover, a pharmaceutical composition containing the compound and an application thereof in the preparation of cancer drugs are also provided.
-
公开(公告)号：US20220235032A1
公开(公告)日：2022-07-28
申请号：US17610112
申请日：2020-05-09
发明人： Fusheng ZHOU , Xiaoming XU , Leitao ZHANG , Tao JIANG , Yingtao LIU , Jiong LAN
IPC分类号： C07D401/14 , C07D403/14
摘要： A substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition is a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.
-
公开(公告)号：US20230203060A1
公开(公告)日：2023-06-29
申请号：US17927961
申请日：2021-05-27
发明人： Fusheng ZHOU , Tao JIANG , Yingtao LIU , Jichen ZHAO , Wan HE , Zhubo LIU , Ling PENG , Lijian CAI , Leitao ZHANG , Chonglan LIN , Huabin YANG , Tao ZHANG , Jiong LAN
IPC分类号： C07D498/14 , C07D519/00 , C07D498/04 , C07D487/14 , A61P35/00
CPC分类号： C07D498/14 , C07D519/00 , C07D498/04 , C07D487/14 , A61P35/00 , C07B2200/05
摘要： Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity. and reduced toxic side effects.
-
公开(公告)号：US20220251109A1
公开(公告)日：2022-08-11
申请号：US17607311
申请日：2020-04-28
发明人： Fusheng ZHOU , Lijian CAI , Tao JIANG , Jichen ZHAO , Yingtao LIU , Jinzhu ZHAO , Leitao ZHANG , Zhubo LIU , Ling PENG , Wan HE , Huabin YANG , Tao ZHANG , Qian DING , Biao ZHENG , Qiang LV , Jiong LAN
IPC分类号： C07D498/22 , C07D498/14 , C07D498/16
摘要： An oxaazaquinazolin-7(8H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salts thereof, stereoisomers, solvent compounds or prodrugs (as shown in formula I or formula II, see the details of the definition to each group in the formulas in the specification), as well as the pharmaceutical composition containing the compound, and the application thereof in preparation of cancer medicine.
-
公开(公告)号：US11236112B2
公开(公告)日：2022-02-01
申请号：US16771977
申请日：2018-12-13
发明人： Lifang Wu , Huijun He , Jianyu Lu , Charles Z. Ding , Lihong Hu , Weidong Li , Shenyi Shi , Jian Li , Shuhui Chen
IPC分类号： C07D519/00 , A61P35/00 , A61K31/444 , A61K31/416 , A61K31/4439 , C07D487/04 , C07D471/04
摘要： Disclosed in the present invention are a crystal form and salt form of a TGF-βR1 inhibitor and a preparation method therefor, and further disclosed is an application of the crystal form and the salt form in preparation of medicines for treating cancers.
-
7.发明申请公开(公告)号：US20190151299A1
公开(公告)日：2019-05-23
申请号：US16308859
申请日：2017-06-08
发明人： Fei SUN , Lifang WU , Charles Z. DING , Guoping HU , Jian LI , Shuhui CHEN , Jianyu LU
IPC分类号： A61K31/4439 , A61P35/00
摘要： A benzotriazole-derived α and β-unsaturated amide compound used as TGF-βR1 inhibitor or a pharmaceutically acceptable salt thereof, the structure of the compound being as shown in formula (I).
-
公开(公告)号：US20240360154A1
公开(公告)日：2024-10-31
申请号：US18245167
申请日：2021-09-21
发明人： Fusheng ZHOU , Tao JIANG , Yingtao LIU , Chonglan LIN , Leitao ZHANG , Zhubo LIU , Kai MA , Wan HE , Xiaoming XU , Lijian FENG , Xiaoling LAN , Qian DING , Qiang LV , Jiong LAN
IPC分类号： C07D498/22 , A61K31/4985 , A61K31/5386 , A61P35/00 , C07D471/14 , C07D471/22 , C07D491/22
CPC分类号： C07D498/22 , A61K31/4985 , A61K31/5386 , A61P35/00 , C07D471/14 , C07D471/22 , C07D491/22
摘要： Disclosed are an aroyl substituted tricyclic compound, a preparation method therefor and use thereof. Specifically, the aroyl substituted tricyclic compound of the present invention has a structure of formula (C), and has, as a BTK inhibitor, the advantages of high activity, good selectivity and low toxic and side effects.
-
9.发明公开公开(公告)号：US20240158417A1
公开(公告)日：2024-05-16
申请号：US18381121
申请日：2023-10-17
发明人： Fusheng ZHOU , Tao JIANG , Chonglan LIN , Lijian CAI , Wan HE , Jiong LAN
IPC分类号： C07D498/22 , C07D471/16 , C07D471/22
CPC分类号： C07D498/22 , C07D471/16 , C07D471/22
摘要： A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
-
10.发明申请公开(公告)号：US20230139111A1
公开(公告)日：2023-05-04
申请号：US17799637
申请日：2021-02-09
发明人： Fusheng ZHOU , Xiaoming XU , Leitao ZHANG , Xin LI , Lili TANG , Jiong LAN
IPC分类号： A61K31/4375 , A61K31/5025 , A61K31/4184 , A61K31/4188 , A61K31/423
摘要： Provided are a dihydronaphthyridinone compound as shown in formula (I), which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. In addition, provided are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.035 秒)
